618 related articles for article (PubMed ID: 18324472)
1. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
2. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
[TBL] [Abstract][Full Text] [Related]
3. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
4. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
[TBL] [Abstract][Full Text] [Related]
5. Race and the prognostic influence of p53 in women with breast cancer.
Dookeran KA; Dignam JJ; Holloway N; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2012 Jul; 19(7):2334-44. PubMed ID: 22434242
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
[TBL] [Abstract][Full Text] [Related]
8. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
9. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
10. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
[TBL] [Abstract][Full Text] [Related]
11. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Carey LA; Perou CM; Livasy CA; Dressler LG; Cowan D; Conway K; Karaca G; Troester MA; Tse CK; Edmiston S; Deming SL; Geradts J; Cheang MC; Nielsen TO; Moorman PG; Earp HS; Millikan RC
JAMA; 2006 Jun; 295(21):2492-502. PubMed ID: 16757721
[TBL] [Abstract][Full Text] [Related]
12. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.
Dickens C; Duarte R; Zietsman A; Cubasch H; Kellett P; Schüz J; Kielkowski D; McCormack V
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2311-21. PubMed ID: 25143359
[TBL] [Abstract][Full Text] [Related]
13. Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium.
Luyeye Mvila G; Batalansi D; Praet M; Marchal G; Laenen A; Christiaens MR; Brouckaert O; Ali-Risasi C; Neven P; Van Ongeval C
Breast; 2015 Oct; 24(5):642-8. PubMed ID: 26279132
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of triple-negative tumors in an urban cancer center.
Lund MJ; Butler EN; Bumpers HL; Okoli J; Rizzo M; Hatchett N; Green VL; Brawley OW; Oprea-Ilies GM; Gabram SG
Cancer; 2008 Aug; 113(3):608-15. PubMed ID: 18484596
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of triple-negative breast cancer, including race.
Trivers KF; Lund MJ; Porter PL; Liff JM; Flagg EW; Coates RJ; Eley JW
Cancer Causes Control; 2009 Sep; 20(7):1071-82. PubMed ID: 19343511
[TBL] [Abstract][Full Text] [Related]
16. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
17. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
18. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
[TBL] [Abstract][Full Text] [Related]
19. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
20. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma.
Porter PL; Lund MJ; Lin MG; Yuan X; Liff JM; Flagg EW; Coates RJ; Eley JW
Cancer; 2004 Jun; 100(12):2533-42. PubMed ID: 15197793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
